Paid Clinical Trials Paid Clinical Trials > Browse Categories > Medications / Interventions > Drugs by Classification > Statins > Lipitor

Lipitor

Lipitor

All Categories Medications / Interventions » Drugs by Classification » Statins » Lipitor


  • Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

    Condition:   HIV Dementia
    Interventions:   Drug: Lipitor;   Drug: placebo
    Sponsors:   University of Pennsylvania;   University of Pennsylvania
    Not yet recruiting - verified May 2012
  • Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial

    Condition:   Type 1 Diabetes
    Interventions:   Drug: Statin;   Drug: Ace Inhibitor;   Drug: Placebo;   Drug: Combination therapy
    Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   Cambridge University Hospitals NHS Foundation Trust;   Juvenile Diabetes Research Foundation;   Diabetes UK;   British Heart Foundation;   Pfizer;   The University of Western Australia;   The Hospital for Sick Children;   University of Oxford;   St Thomas' Hospital, London
    Recruiting - verified April 2012
  • Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

    Condition:   Carotid Stenosis
    Interventions:   Drug: Clopidogrel;   Drug: Atorvastatin
    Sponsors:   Campus Bio-Medico University;   Campus Bio-Medico University
    Recruiting - verified April 2012
  • Renal Denervation in Diabetic Nephropathy

    Conditions:   Diabetic Nephropathy;   Persistent Proteinuria With Type II Diabetes
    Interventions:   Procedure: Percutaneous renal denervation and TMNS;   Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
    Sponsors:   Assistance Publique - Hôpitaux de Paris;   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting - verified March 2012
  • Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity

    Condition:   Coronary Artery Disease
    Interventions:   Drug: Atorvastatin;   Drug: Rosuvastatin
    Sponsors:   University of Roma La Sapienza;   University of Roma La Sapienza
    Not yet recruiting - verified March 2012
  • Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

    Condition:   Coronary Artery Disease
    Interventions:   Drug: standard of care lipid therapy (Zocor, Lipitor, Crestor);   Drug: Aggressive lipid therapy with Crestor 40mg
    Sponsors:   Mount Sinai School of Medicine;   Annapoorna Kini
    Recruiting - verified March 2012
  • Genetic Influence on Statin Pharmacokinetics

    Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Dyslipidemia
    Intervention:  
    Sponsors:   Ohio State University;   Ohio State University;   National Institute of General Medical Sciences (NIGMS)
    Recruiting - verified March 2012
  • Genetic Influence on Statin Pharmacodynamics

    Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Dyslipidemia
    Intervention:  
    Sponsors:   Ohio State University;   Ohio State University;   National Institute of General Medical Sciences (NIGMS)
    Recruiting - verified March 2012
  • Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives

    Conditions:   Stroke;   Transient Ischemic Attack;   Hypertension
    Intervention:   Drug: all approved antihypertensive drugs; all approved statins
    Sponsors:   Istituto Auxologico Italiano;   Istituto Auxologico Italiano;   European Society of Hypertension;   Chinese Hypertension League
    Not yet recruiting - verified March 2012
  • Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation

    Condition:   Drug-eluting Stent (DES)
    Interventions:   Drug: Atorvastatin (High dose statin treatment);   Drug: Pravastatin (High dose statin treatment)
    Sponsors:   Yonsei University;   Yonsei University
    Recruiting - verified March 2012
  • Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke

    Conditions:   Ventilator-associated Pneumonia;   Ischemic Stroke
    Interventions:   Drug: Atorvastatin;   Drug: Placebo
    Sponsors:   Shanghai Minhang Central Hospital;   Shanghai Minhang Central Hospital;   Shanghai Jiao Tong University School of Medicine
    Recruiting - verified March 2012
  • Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery

    Condition:   Atrial Fibrillation
    Interventions:   Procedure: Cardiac surgery;   Procedure: Cardiac surgery
    Sponsors:   Fundación General Universidad de Valladolid;   Fundación General Universidad de Valladolid
    Recruiting - verified March 2012
  • Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose

    Conditions:   Myocardial Infarction;   Peripheral Vascular Disease;   Aortic Aneurism
    Interventions:   Drug: Atorvastatin;   Drug: Placebo
    Sponsors:   Hospital do Coracao;   Hospital do Coracao
    Not yet recruiting - verified April 2012
  • Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery

    Condition:   Acute Kidney Injury
    Interventions:   Drug: Atorvastatin(Lipitor);   Drug: Placebo
    Sponsors:   Peking Union Medical College;   Peking Union Medical College;   Cardiovascular Institute & Fuwai Hospital
    Recruiting - verified April 2012
  • Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

    Conditions:   Essential Hypertension;   Hyperlipidemia
    Interventions:   Drug: Atorvastatin;   Drug: Losartan;   Drug: Placebo;   Drug: HL-040XC
    Sponsors:   HanAll BioPharma Co., Ltd.;   HanAll BioPharma Co., Ltd.
    Not yet recruiting - verified February 2012
  • LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts

    Condition:   Hypercholesterolemia With Concomitant Type 2 Diabetes
    Interventions:   Drug: Atorvastatin;   Drug: Rosuvastatin
    Sponsors:   Listen Trial Group;   Listen Trial Group
    Recruiting - verified April 2012
  • Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin

    Condition:   Nonalcoholic Fatty Liver Disease (NAFLD)
    Interventions:   Drug: Low dose metformin;   Drug: Metformin;   Drug: Atorvastatin
    Sponsors:   University Magna Graecia;   Prof Antonino Belfiore
    Recruiting - verified February 2012
  • Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

    Conditions:   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
    Interventions:   Drug: atorvastatin calcium;   Drug: placebo
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

    Condition:   Saphenous Vein Graft Disease
    Interventions:   Drug: Atorvastatin 80 mg daily;   Drug: Atorvastatin 10 mg daily
    Sponsors:   Boca Raton Regional Hospital;   Boca Raton Regional Hospital;   Pfizer
    Recruiting - verified March 2012
  • Donor Atorvastatin Calcium in Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Blood Stem Cell Transplant

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Disseminated Neuroblastoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   High Risk Metastatic Gestational Trophoblastic Tumor;   Juvenile Myelomonocytic Leukemia;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Gestational Trophoblastic Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroblastoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Breast Cancer;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: atorvastatin calcium;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2012
  • Atorvastatin Calcium-Treated Donor Peripheral Blood Stem Cell Transplant in Preventing Severe Graft-Versus-Host Disease in Patients With Hematological Malignancies

    Conditions:   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: atorvastatin calcium;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2012
  • Influence of Atorvastatin on Psoriasis Severity and Endothelial Function

    Condition:   Psoriasis
    Interventions:   Drug: Atorvastatin;   Drug: Atorvastatin placebo
    Sponsors:   Rabin Medical Center;   shmuel fuchs
    Not yet recruiting - verified February 2012
  • Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

    Condition:   Stroke
    Interventions:   Procedure: autologous hematopoiesis stem cell transplantation;   Drug: Aspirin;   Drug: Warfarin;   Drug: Atorvastatin;   Drug: Edaravone;   Drug: Aspirin;   Drug: Warfarin;   Drug: Atorvastatin;   Drug: Edaravone
    Sponsors:   Zhejiang Hospital;   Zhejiang Hospital;   Zhejiang University
    Recruiting - verified January 2012
  • Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients

    Condition:   Heart Failure
    Interventions:   Drug: Atorvastatin;   Drug: Placebo
    Sponsors:   National Taiwan University Hospital;   National Taiwan University Hospital
    Recruiting - verified November 2011
  • A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: 1mg Glimepiride/10mg Atorvastatin FDC;   Drug: 2mg Glimepiride/10mg Atorvastatin FDC;   Drug: 3mg Glimepiride/10mg Atorvastatin FDC;   Drug: 4mg Glimepiride/10mg Atorvastatin FDC;   Drug: 1mg Glimepiride/20mg Atorvastatin FDC;   Drug: 2mg Glimepiride/20mg Atorvastatin FDC;   Drug: 3mg Glimepiride/20mg Atorvastatin FDC;   Drug: 4mg Glimepiride/20mg Atorvastatin FDC;   Drug: 1mg Glimepiride;   Drug: 2mg Glimepiride;   Drug: 3mg Glimepiride;   Drug: 4mg Glimepiride;   Drug: 10mg Atorvastatin;   Drug: 20mg Atorvastatin
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified February 2012
  • Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: atorvastatin;   Drug: Tacrolimus;   Drug: methotrexate
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center
    Recruiting - verified January 2012
  • A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.

    Condition:   Cardiovascular Diseases
    Interventions:   Drug: AMR101;   Drug: Placebo
    Sponsors:   Amarin Pharma Inc.;   Amarin Pharma Inc.
    Recruiting - verified March 2012
  • Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading

    Condition:   Acute Coronary Syndrome
    Interventions:   Drug: Pre-procedural High dose atorvastatin loading;   Drug: No pre-procedural high-dose atorvastatin loading
    Sponsors:   The Korean Society of Circulation;   The Korean Society of Circulation
    Recruiting - verified December 2011
  • A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Sitagliptin;   Drug: Atorvastatin;   Other: Placebo to sitagliptin;   Other: Placebo to atorvastatin;   Drug: Metformin;   Drug: Glimepiride;   Drug: Placebo to glimepiride
    Sponsors:   Merck;   Merck
    Recruiting - verified May 2012
  • Statins Evaluation in Coronary Procedures and Revascularization Trial

    Condition:   Acute Coronary Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Placebo
    Sponsors:   Hospital do Coracao;   Hospital do Coracao;   Ministry of Health, Brazil
    Not yet recruiting - verified February 2012
  • Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

    Conditions:   Renal Failure Chronic Requiring Hemodialysis;   Metabolic Syndrome;   Diabetes Mellitus Type 2;   Hyperlipidemia
    Intervention:   Drug: Atorvastatin
    Sponsors:   Poznan University of Medical Sciences;   Poznan University of Medical Sciences
    Recruiting - verified October 2011
  • Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

    Condition:   Stroke
    Interventions:   Drug: Anti-platelets and statin;   Drug: alteplase;   Procedure: intra arterial intervention
    Sponsors:   Jacobs Neurological Institute;   Jacobs Neurological Institute;   University at Buffalo Neurosurgery;   Genentech
    Recruiting - verified March 2012
  • Special Drug Use-Results Survey of Lipitor Tablets

    Condition:   Hypercholesterolemia
    Intervention:   Drug: atrovastatin
    Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
    Recruiting - verified October 2011
  • Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention

    Condition:   Platelet Dysfunction
    Interventions:   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Placebo
    Sponsors:   IRCCS San Raffaele;   IRCCS San Raffaele
    Recruiting - verified February 2012
  • Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

    Condition:   Kawasaki Disease
    Intervention:   Drug: Atorvastatin
    Sponsors:   University of California, San Diego;   University of California, San Diego
    Not yet recruiting - verified September 2011
  • Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial

    Conditions:   Immune Reconstitution Inflammatory Syndrome;   Immune Reconstitution Syndrome;   Tuberculosis;   HIV-infection/Aids
    Interventions:   Drug: Dexamethasone;   Drug: Atorvastatin;   Drug: Naproxen;   Drug: Placebo
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   Pfizer;   Minnesota Medical Foundation
    Not yet recruiting - verified April 2012
  • Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy

    Condition:   Stable Angina
    Interventions:   Device: Endothelial cell capture stent with 1 month clopidogrel;   Device: Everolimus eluting stent with 12 month clopidogrel;   Drug: Atorvastatin 20mg loading;   Drug: Atorvastatin 80mg loading
    Sponsors:   Yonsei University;   Yonsei University;   OrbusNeich;   Yuhan Corporation
    Not yet recruiting - verified March 2012
  • Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

    Conditions:   Hypertension;   Hyperlipidemia
    Interventions:   Drug: Irbesartan/Atorvastatin A;   Drug: Irbesartan;   Drug: Atorvastatin A;   Drug: Placebo;   Drug: Irbesartan/Atorvastatin B;   Drug: Atorvastatin B
    Sponsors:   Hanmi Pharmaceutical Company Limited;   Hanmi Pharmaceutical Company Limited
    Recruiting - verified September 2011
  • Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

    Condition:   Hyperlipidemia
    Interventions:   Drug: Pitavastatin;   Drug: Atorvastatin
    Sponsors:   Tai Tien Pharmaceuticals Co., Ltd.;   Tai Tien Pharmaceuticals Co., Ltd.
    Not yet recruiting - verified June 2011
  • Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.

    Condition:   ST-Segment Elevation Myocardial Infarction
    Interventions:   Drug: Ezetimibe;   Drug: Placebo
    Sponsors:   Odense University Hospital;   Odense University Hospital
    Recruiting - verified June 2011
  • Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome

    Conditions:   Myocardial Infarction;   Unstable Angina
    Interventions:   Drug: Atorvastatin;   Drug: Statin
    Sponsors:   Xijing Hospital;   Xijing Hospital
    Recruiting - verified July 2010
  • Diabetic Treatment Adherence

    Condition:   Endocrine System Diseases
    Interventions:   Drug: Metformin;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Agency for Healthcare Research and Quality (AHRQ)
    Recruiting - verified March 2012
  • Modulation of Monocyte Activation by Atorvastatin in HIV Infection

    Condition:   HIV Dementia
    Intervention:   Drug: Atorvastatin
    Sponsors:   University of Pennsylvania;   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified May 2012
  • Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design

    Condition:   Statin Myopathy
    Intervention:   Drug: Individual-specific statin causing myopathy
    Sponsors:   Lawson Health Research Institute;   Lawson Health Research Institute
    Recruiting - verified June 2011
  • Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

    Condition:   HIV-1 Infection
    Interventions:   Drug: atorvastatin;   Drug: atorvastatin
    Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Pfizer
    Recruiting - verified September 2011
  • Sunitinib and Atrial Trabeculae Contractility

    Conditions:   Cardiotoxicity;   Ischemia;   Heart Failure
    Intervention:  
    Sponsors:   Radboud University;   Radboud University
    Recruiting - verified October 2010
  • Statins in Children With Type 1 Diabetes and Hypercholesterolemia

    Conditions:   Diabetes Mellitus, Insulin-Dependent;   Hypercholesterolemia
    Interventions:   Drug: Atorvastatin;   Drug: Atorvastatin Placebo
    Sponsors:   Nemours Children's Clinic;   Nemours Children's Clinic;   Pfizer;   Medtronic;   Quest Diagnostics
    Recruiting - verified May 2012
  • Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa

    Condition:   BRONCHIECTASIS
    Intervention:   Drug: ATORVASTATIN
    Sponsors:   University of Edinburgh;   University of Edinburgh;   NHS Lothian
    Recruiting - verified November 2011
  • A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis

    Condition:   Bronchiectasis
    Intervention:   Drug: Atorvastatin
    Sponsors:   University of Edinburgh;   University of Edinburgh;   NHS Lothian
    Recruiting - verified November 2011
  • MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)

    Condition:   Hypercholesterolemia
    Interventions:   Drug: ezetimibe (+) atorvastatin;   Drug: Comparator: ezetimibe (+) atorvastatin;   Drug: Comparator: atorvastatin, switching to ezetimibe (+) atorvastatin;   Drug: Comparator: atorvastatin;   Drug: Comparator: rosuvastatin, switching to ezetimibe (+) atorvastatin;   Drug: Comparator: rosuvastatin
    Sponsors:   Merck;   Merck
    Recruiting - verified May 2012
  • Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients

    Condition:   Acute Heart Failure
    Intervention:   Drug: statin
    Sponsors:   Yonsei University;   Yonsei University
    Recruiting - verified August 2011
  • To Investigate the Role of Upstream High Dose Statin in STEMI

    Condition:   Acute Myocardial Infarction
    Interventions:   Drug: Atorvastatin calcium;   Drug: Inactive Placebo
    Sponsors:   The Western Pennsylvania Hospital;   The Western Pennsylvania Hospital;   West Penn Allegheny Health System
    Recruiting - verified August 2011
  • Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients

    Condition:   Acute Coronary Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Atorvastatin
    Sponsors:   Shanghai Jiao Tong University School of Medicine;   Shanghai Jiao Tong University School of Medicine
    Recruiting - verified February 2011
  • Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome

    Condition:   Acute Coronary Syndrome
    Interventions:   Procedure: Percutaneous coronary intervention;   Procedure: Intravascular ultrasound with virtual histology;   Drug: Atorvastatin;   Device: LDL-apheresis
    Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
    Recruiting - verified March 2012
  • Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

    Condition:   Coronary Artery Disease
    Intervention:   Drug: Atorvastatin
    Sponsors:   Indiana University;   Indiana University School of Medicine;   National Center for Research Resources (NCRR)
    Recruiting - verified November 2010
  • Statin Therapy to Improve Atherosclerosis in HIV Patients

    Conditions:   Cardiovascular Disease;   HIV;   Atherosclerosis;   Inflammation;   Statins, HMG-CoA;   HIV Infections
    Interventions:   Drug: atorvastatin;   Drug: Placebo
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2012
  • Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes

    Conditions:   Type 2 Diabetes;   Atherosclerosis
    Intervention:   Drug: Atorvastatin
    Sponsors:   Korea University;   Korea University
    Not yet recruiting - verified July 2009
  • Cardiopulmonary-bypass and Reno-protective Effect of Atorvastatin Trial.

    Condition:   Acute Kidney Dysfunction
    Interventions:   Drug: Atorvastatin;   Drug: Placebo
    Sponsors:   Austin Health;   Austin Health
    Recruiting - verified August 2009
  • Atorvastatin Three Year Pediatric Study

    Condition:   Familial Hypercholesterolemia
    Intervention:   Drug: atorvastatin
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified April 2012
  • Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial

    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: Adalimumab;   Drug: Lisinopril, losartan, and atorvastatin;   Drug: galactose
    Sponsors:   New York University School of Medicine;   New York University School of Medicine;   University of Michigan;   The Cleveland Clinic;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified April 2012
  • Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis

    Conditions:   Carotid Artery Stenosis;   Atherosclerosis;   Stroke
    Interventions:   Procedure: Carotid Endarterectomy;   Drug: atorvastatin, aspirin, losartan, amlodipine
    Sponsors:   Russian Cardiology Research and Production Center;   Russian Cardiology Research and Production Center;   Krka, d.d., Novo mesto, Slovenia
    Recruiting - verified June 2011
  • Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

    Conditions:   Acute Kidney Injury;   Post-Operative Delirium;   Icu Delirium;   Acute Renal Failure;   Delirium
    Interventions:   Drug: atorvastatin;   Drug: placebo
    Sponsors:   Vanderbilt University;   Vanderbilt University
    Recruiting - verified July 2011
  • Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

    Condition:   HDL Cholesterol
    Interventions:   Drug: Simvastatin;   Drug: Atorvastatin 80 mg
    Sponsors:   Oregon Health and Science University;   Oregon Health and Science University;   Merck;   Oregon State University;   Indiana University
    Recruiting - verified August 2008
  • Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

    Conditions:   HIV Infections;   Hyperlipidemia
    Intervention:   Drug: Atorvastatin
    Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified May 2012
  • Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study

    Condition:   Coronary Heart Disease
    Interventions:   Behavioral: smoking cessation;   Drug: betablocker, diuretics, ACEI, ARB,;   Drug: statins (simvastatin, atorvastatin), ezetimib;   Behavioral: training;   Biological: influenza vaccine;   Drug: metformin, glimepiride, insulin;   Behavioral: weight reduction
    Sponsors:   Sorlandet Hospital HF;   Sorlandet Hospital HF;   Ullevaal University Hospital
    Recruiting - verified December 2011
  • Atorvastatin to Treat Pulmonary Sarcoidosis

    Condition:   Sarcoidosis, Pulmonary
    Intervention:   Drug: Atorvastatin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2011
  • Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

    Conditions:   Leukemia;   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Atorvastatin;   Procedure: CT scan of chest/abdomen/pelvis
    Sponsors:   Stanford University;   Stanford University;   The Leukemia and Lymphoma Society;   Damon Runyon Cancer Research Foundation;   Burroughs Wellcome
    Recruiting - verified November 2011

Main Menu
Clinical Trial Categories
Clinical Trial Locations